Chapter 2: Use of iron to treat anemia in CKD

Kidney International Supplements

Volumn 2, Issue 4, 2012, Pages 292-298

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85054693581     PISSN: 21571724     EISSN: 21571716     Source Type: Journal    
DOI: 10.1038/kisup.2012.34     Document Type: Article

References (90)

1. Locatelli, F., Aljama, P., Barany, P., et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 19:Suppl 2 (2004), ii1–i47.
2. Rambod, M., Kovesdy, C.P., Kalantar-Zadeh, K., Combined high serum ferritin and low iron saturation in hemodialysis patients: the role of inflammation. Clin J Am Soc Nephrol 3 (2008), 1691–1701.
3. Kalantar-Zadeh, K., Hoffken, B., Wunsch, H., et al. Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis 26 (1995), 292–299.
4. Aljama, P., Ward, M.K., Pierides, A.M., et al. Serum ferritin concentration: a reliable guide to iron overload in uremic and hemodialyzed patients. Clin Nephrol 10 (1978), 101–104.
5. Barany, P., Eriksson, L.C., Hultcrantz, R., et al. Serum ferritin and tissue iron in anemic dialysis patients. Miner Electrolyte Metab 23 (1997), 273–276.
6. Blumberg, A.B., Marti, H.R., Graber, C.G., Serum ferritin and bone marrow iron in patients undergoing continuous ambulatory peritoneal dialysis. JAMA 250 (1983), 3317–3319.
7. Hussein, S., Prieto, J., O′Shea, M., et al. Serum ferritin assay and iron status in chronic renal failure and haemodialysis. Br Med J 1 (1975), 546–548.
8. Mirahmadi, K.S., Paul, W.L., Winer, R.L., et al. Serum ferritin level. Determinant of iron requirement in hemodialysis patients. JAMA 238 (1977), 601–603.
9. Tessitore, N., Girelli, D., Campostrini, N., et al. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol Dial Transplant 25 (2010), 3996–4002.
10. Tessitore, N., Solero, G.P., Lippi, G., et al. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 16 (2001), 1416–1423.
11. Mircescu, G., Garneata, L., Capusa, C., et al. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients. Nephrol Dial Transplant 21 (2006), 120–124.
12. Silverberg, D.S., Iaina, A., Peer, G., et al. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis 27 (1996), 234–238.
13. Fishbane, S., Frei, G.L., Maesaka, J., Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26 (1995), 41–46.
14. Sunder-Plassmann, G., Horl, W.H., Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 10 (1995), 2070–2076.
15. Fishbane, S., Maesaka, J.K., Iron management in end-stage renal disease. Am J Kidney Dis 29 (1997), 319–333.
16. Fishbane, S., Kowalski, E.A., Imbriano, L.J., et al. The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 7 (1996), 2654–2657.
17. Fishbane, S., Shapiro, W., Dutka, P., et al. A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int 60 (2001), 2406–2411.
18. Macdougall, I.C., Tucker, B., Thompson, J., et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50 (1996), 1694–1699.
19. Feldman, H.I., Joffe, M., Robinson, B., et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 15 (2004), 1623–1632.
20. Feldman, H.I., Santanna, J., Guo, W., et al. Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 13 (2002), 734–744.
21. Kalantar-Zadeh, K., Regidor, D.L., McAllister, C.J., et al. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 16 (2005), 3070–3080.
22. Chang, C.H., Chang, C.C., Chiang, S.S., Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients. Clin Nephrol 57 (2002), 136–141.
23. Senger, J.M., Weiss, R.J., Hematologic and erythropoietin responses to iron dextran in the hemodialysis environment. ANNA J 23 (1996), 319–323 discussion 324–315.
24. Spinowitz, B.S., Kausz, A.T., Baptista, J., et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 19 (2008), 1599–1605.
25. Silverberg, D.S., Blum, M., Agbaria, Z., et al. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period. Clin Nephrol 55 (2001), 212–219.
26. Stancu, S., Barsan, L., Stanciu, A., et al. Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease?. Clin J Am Soc Nephrol 5 (2010), 409–416.
27. Besarab, A., Kaiser, J.W., Frinak, S., A study of parenteral iron regimens in hemodialysis patients. Am J Kidney Dis 34 (1999), 21–28.
28. DeVita, M.V., Frumkin, D., Mittal, S., et al. Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients. Clin Nephrol 60 (2003), 335–340.
29. Navarro, J.F., Teruel, J.L., Liano, F., et al. Effectiveness of intravenous administration of Fe-gluconate-Na complex to maintain adequate body iron stores in hemodialysis patients. Am J Nephrol 16 (1996), 268–272.
30. Anker, S.D., Comin Colet, J., Filippatos, G., et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361 (2009), 2436–2448.
31. Van Wyck, D.B., Roppolo, M., Martinez, C.O., et al. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 68 (2005), 2846–2856.
32. Ford, B.A., Coyne, D.W., Eby, C.S., et al. Variability of ferritin measurements in chronic kidney disease; implications for iron management. Kidney Int 75 (2009), 104–110.
33. Fishbane, S., Upper limit of serum ferritin: misinterpretation of the 2006 KDOQI anemia guidelines. Semin Dial 21 (2008), 217–220.
34. Fishbane, S., Kalantar-Zadeh, K., Nissenson, A.R., Serum ferritin in chronic kidney disease: reconsidering the upper limit for iron treatment. Semin Dial 17 (2004), 336–341.
35. National Kidney Foundation, NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis 37 (2001), S182–S238.
36. National Kidney Foundation, KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47 (2006), S1–S146.
37. National Kidney Foundation, KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 50 (2007), 471–530.
38. Locatelli, F., Covic, A., Eckardt, K.U., et al. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant 24 (2009), 348–354.
39. Coyne, D.W., Kapoian, T., Suki, W., et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients′ Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 18 (2007), 975–984.
40. Canavese, C., Bergamo, D., Ciccone, G., et al. Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int 65 (2004), 1091–1098.
41. Ferrari, P., Kulkarni, H., Dheda, S., et al. Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol 6 (2011), 77–83.
42. Caramelo, C., Albalate, M., Bermejillo, T., et al. Relationships between plasma ferritin and aminotransferase profile in haemodialysis patients with hepatitis C virus. Nephrol Dial Transplant 11 (1996), 1792–1796.
43. Morrison, E.D., Brandhagen, D.J., Phatak, P.D., et al. Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Ann Intern Med 138 (2003), 627–633.
44. National Kidney Foundation, KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Section III. Clinical practice recommendations for anemia in chronic kidney disease in children. Am J Kidney Dis 47 (2006), S86–108.
45. Agarwal, R., Rizkala, A.R., Bastani, B., et al. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol 26 (2006), 445–454.
46. Aggarwal, H.K., Nand, N., Singh, S., et al. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. J Assoc Physicians India 51 (2003), 170–174.
47. Charytan, C., Qunibi, W., Bailie, G.R., Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract 100 (2005), c55–c62.
48. Rozen-Zvi, B., Gafter-Gvili, A., Paul, M., et al. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis 52 (2008), 897–906.
49. Stoves, J., Inglis, H., Newstead, C.G., A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant 16 (2001), 967–974.
50. Allegra, V., Mengozzi, G., Vasile, A., Iron deficiency in maintenance hemodialysis patients: assessment of diagnosis criteria and of three different iron treatments. Nephron 57 (1991), 175–182.
51. Li, H., Wang, S.X., Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia. Blood Purif 26 (2008), 151–156.
52. Ahsan, N., Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dialysis patients: a single center comparative study. J Am Soc Nephrol 9 (1998), 664–668.
53. Johnson, D.W., Herzig, K.A., Gissane, R., et al. A prospective crossover trial comparing intermittent intravenous and continuous oral iron supplements in peritoneal dialysis patients. Nephrol Dial Transplant 16 (2001), 1879–1884.
54. Johnson, D.W., Herzig, K.A., Gissane, R., et al. Oral versus intravenous iron supplementation in peritoneal dialysis patients. Perit Dial Int 21:Suppl 3 (2001), S231–S235.
55. Li, H., Wang, S.X., Intravenous iron sucrose in peritoneal dialysis patients with renal anemia. Perit Dial Int 28 (2008), 149–154.
56. Singh, H., Reed, J., Noble, S., et al. Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial. Clin J Am Soc Nephrol 1 (2006), 475–482.
57. Eschbach, J.W., Cook, J.D., Scribner, B.H., et al. Iron balance in hemodialysis patients. Ann Intern Med 87 (1977), 710–713.
58. Sargent, J.A., Acchiardo, S.R., Iron requirements in hemodialysis. Blood Purif 22 (2004), 112–123.
59. Schaefer, R.M., Schaefer, L., Iron monitoring and supplementation: how do we achieve the best results?. Nephrol Dial Transplant 13:Suppl 2 (1998), 9–12.
60. Besarab, A., Amin, N., Ahsan, M., et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 11 (2000), 530–538.
61. Ruiz-Jaramillo Mde, L., Guizar-Mendoza, J.M., Gutierrez-Navarro Mde, J., et al. Intermittent versus maintenance iron therapy in children on hemodialysis: a randomized study. Pediatr Nephrol 19 (2004), 77–81.
62. Schroder, C.H., The management of anemia in pediatric peritoneal dialysis patients. Guidelines by an ad hoc European committee. Pediatr Nephrol 18 (2003), 805–809.
63. Van Damme-Lombaerts, R., Herman, J., Erythropoietin treatment in children with renal failure. Pediatr Nephrol 13 (1999), 148–152.
64. Warady, B.A., Kausz, A., Lerner, G., et al. Iron therapy in the pediatric hemodialysis population. Pediatr Nephrol 19 (2004), 655–661.
65. Warady, B.A., Zobrist, R.H., Wu, J., et al. Sodium ferric gluconate complex therapy in anemic children on hemodialysis. Pediatr Nephrol 20 (2005), 1320–1327.
66. Warady, B.A., Zobrist, R.H., Finan, E., Sodium ferric gluconate complex maintenance therapy in children on hemodialysis. Pediatr Nephrol 21 (2006), 553–560.
67. Anbu, A.T., Kemp, T., O′Donnell, K., et al. Low incidence of adverse events following 90-minute and 3-minute infusions of intravenous iron sucrose in children on erythropoietin. Acta Paediatr 94 (2005), 1738–1741.
68. Bailie, G.R., Clark, J.A., Lane, C.E., et al. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant 20 (2005), 1443–1449.
69. Charytan, C., Schwenk, M.H., Al-Saloum, M.M., et al. Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products. Nephron Clin Pract 96 (2004), c63–c66.
70. Fishbane, S., Ungureanu, V.D., Maesaka, J.K., et al. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 28 (1996), 529–534.
71. Fletes, R., Lazarus, J.M., Gage, J., et al. Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis 37 (2001), 743–749.
72. Jain, A.K., Bastani, B., Safety profile of a high dose ferric gluconate in patients with severe chronic renal insufficiency. J Nephrol 15 (2002), 681–683.
73. Lu, M., Cohen, M.H., Rieves, D., et al. FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol 85 (2010), 315–319.
74. Macdougall, I.C., Roche, A., Administration of intravenous iron sucrose as a 2-minute push to CKD patients: a prospective evaluation of 2,297 injections. Am J Kidney Dis 46 (2005), 283–289.
75. Michael, B., Coyne, D.W., Fishbane, S., et al. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int 61 (2002), 1830–1839.
76. Sav, T., Tokgoz, B., Sipahioglu, M.H., et al. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran?. Ren Fail 29 (2007), 423–426.
77. Ullian, M.E., Gadegbeku, C.A., Effects of intravenously administered iron on systemic blood pressure in hemodialysis patients. Nephron Clin Pract 98 (2004), c83–c86.
78. Auerbach, M., Al Talib, K., Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease. Kidney Int 73 (2008), 528–530.
79. Chertow, G.M., Mason, P.D., Vaage-Nilsen, O., et al. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant 19 (2004), 1571–1575.
80. Chertow, G.M., Mason, P.D., Vaage-Nilsen, O., et al. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 21 (2006), 378–382.
81. McCarthy, J.T., Regnier, C.E., Loebertmann, C.L., et al. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran—a comparison of two products. Am J Nephrol 20 (2000), 455–462.
82. Rodgers, G.M., Auerbach, M., Cella, D., et al. High-molecular weight iron dextran: a wolf in sheep′s clothing?. J Am Soc Nephrol 19 (2008), 833–834.
83. Wessling-Resnick, M., Iron homeostasis and the inflammatory response. Annu Rev Nutr 30 (2010), 105–122.
84. Appelberg, R., Macrophage nutriprive antimicrobial mechanisms. J Leukoc Biol 79 (2006), 1117–1128.
85. Byrd, T.F., Horwitz, M.A., Interferon gamma-activated human monocytes downregulate transferrin receptors and inhibit the intracellular multiplication of Legionella pneumophila by limiting the availability of iron. J Clin Invest 83 (1989), 1457–1465.
86. Mencacci, A., Cenci, E., Boelaert, J.R., et al. Iron overload alters innate and T helper cell responses to Candida albicans in mice. J Infect Dis 175 (1997), 1467–1476.
87. Nairz, M., Theurl, I., Ludwiczek, S., et al. The co-ordinated regulation of iron homeostasis in murine macrophages limits the availability of iron for intracellular Salmonella typhimurium. Cell Microbiol 9 (2007), 2126–2140.
88. Hoen, B., Paul-Dauphin, A., Hestin, D., et al. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 9 (1998), 869–876.
89. Hoen, B., Paul-Dauphin, A., Kessler, M., Intravenous iron administration does not significantly increase the risk of bacteremia in chronic hemodialysis patients. Clin Nephrol 57 (2002), 457–461.
90. Teehan, G.S., Bahdouch, D., Ruthazer, R., et al. Iron storage indices: novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy. Clin Infect Dis 38 (2004), 1090–1094.